[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","dhup1v6z7lg2cpfueznund8o3","revision",2,"title","Clene Inc. 与 NYU 签署 NIH 资助第四年子拨款协议","originalTitle","Clene Inc. (0001822791) (Filer)","summary","Clene Inc. 与 NYU 签署 NIH 资助第四年子拨款协议，金额最高 720 万美元。该协议支持 CNM-Au8 治疗肌萎缩侧索硬化症的扩展准入计划。协议文本作为 8-K 报告附件披露。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-19T23:37:08.000Z","discoveredAt","2026-10-20T10:25:11.951Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",32,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f0uy-6sZm_J8",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","2bc07e5d-a45e-4d2b-a603-35ac0d6e0b4c","Clene Inc. 与 NYU 签署 NIH 资助协议",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2026

CLENE INC.

(Exact name of registrant as specified in its charter)

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t Delaware \n\t\t\t	\n\t\t\t 001-39834 \n\t\t\t	\n\t\t\t 85-2828339 \n\t\t\t
\n\t\t\t (State or other jurisdiction \n\t\t\t	\n\t\t\t (Commission File Number) \n\t\t\t	\n\t\t\t (IRS Employer \n\t\t\t
\n\t\t\t of incorporation) \n\t\t\t		\n\t\t\t Identification No.) \n\t\t\t

\n\t\t\t 6550 South Millrock Drive, Suite G50 \n\n\t\t\t Salt Lake City, Utah \n\t\t\t		\n\t\t\t 84121 \n\t\t\t
\n\t\t\t (Address of principal executive offices) \n\t\t\t		\n\t\t\t (Zip Code) \n\t\t\t

(801) 676-9695

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\t\t\t

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

☐

\n\t\t\t

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

\n\t\t\t

Securities registered pursuant to Section 12(b) of the Act:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t Title of each class \n\t\t\t		\n\t\t\t Trading Symbol(s) \n\t\t\t		\n\t\t\t Name of each exchange on which registered \n\t\t\t
\n\t\t\t Common Stock, $0.0001 par value \n\t\t\t		\n\t\t\t CLNN \n\t\t\t		\n\t\t\t The Nasdaq Capital Market \n\t\t\t

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Previously, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”) announced (i) on October 5, 2023, a four-year, $45.1 million grant (“the NIH Grant”) from the National Institute of Health (“NIH”) to the Company, in collaboration with Synapticure, a neurology specialty health clinical, (ii) on April 9, 2024, a grant subaward agreement for the first year of the NIH Grant with Columbia University (“Columbia”) as prime awardee for up to $7.3 million during the period from September 25, 2023 to August 31, 2024, (iii) on January 30, 2025, a grant subaward amendment for the second year of the NIH Grant with Columbia for up to $8.0 million during the period from September 1, 2024 to August 31, 2025, and (iv) on March 16, 2026, a grant subaward agreement for the third year of the NIH Grant with New York University (“NYU”) as prime awardee for up to $8.0 million during the period from September 1, 2025 to August 31, 2026.

On October 15, 2026, the Company entered into a subaward amendment for the fourth year of the NIH Grant with NYU for up to $7.2 million during the period from September 1, 2026 to August 31, 2027 (the “Subaward”). The other terms of the Subaward as disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2026, remain in full force and effect. The NIH Grant supports an Expanded Access Program for CNM-Au8^® treatment of amyotrophic lateral sclerosis and was awarded under the Accelerating Access to Critical Therapies for ALS Act.

The foregoing description of Subaward does not purport to be complete and is qualified in its entirety by reference to the text of Subaward, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

Exhibit Number		Exhibit Description
10.1		Subaward Amendment, dated October 15, 2026, by and between Clene Nanomedicine, Inc. and NYU.
104		Cover Page Interactive Data File (formatted as Inline XBRL).

\n1\n

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

	\n\t\t\t CLENE INC. \n\t\t\t

\n\t\t\t Date: October 20, 2026 \n\t\t\t	\n\t\t\t By: \n\t\t\t	\n\t\t\t /s/ Robert Etherington \n\t\t\t
		\n\t\t\t Robert Etherington \n\t\t\t
		\n\t\t\t President and Chief Executive Officer \n\t\t\t

\n2\n

","zhKind","complete","CLNN","其他","aihot","/items/dhup1v6z7lg2cpfueznund8o3","https://www.sec.gov/Archives/edgar/data/1822791/000143774926032960/0001437749-26-032960-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792713600&sig=5c6d5f091d1967b7","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792713600&sig=86138d453cd8c096 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792713600&sig=e067c63cbf80f0de 96w","changelogVersion","2026-10-01T08:00"]